Services Marketing of COVID-19 Vaccines in the Present Scenario

The global COVID-19 vaccines market is projected to reach USD 1,401 million by 2025 from USD 2,273million in 2022, at a CAGR of -14.9% during the forecast period. The growth of the COVID vaccines market isattributed majorly to the rising number of people infected with COVID-19 and increasing funding for vaccinedevelopment.On the other hand, the global COVID-19 drugs market is projected to reach USD 2 million by 2025 fromUSD 165 million in 2020, at a CAGR of -57.8% during the forecast period. The growth of the COVID drugsmarket is primarily attributed to use of repurposed drugs for compassionate use, and the emergence ofalternative therapies such as convalescent plasma therapy which were earlier used for treating epidemicdiseases such as SARS, MERS, and H1N1. Moreover, collaborations between global organizations andgovernments of various nations to promote the supply of essential drugs and medical supplies are fueling themarket growth.Researchers worldwide are working around the clock to find a vaccine against SARS-CoV-2, the viruscausing the COVID-19 pandemic. The Herculean effort means that a fast-tracked vaccine could come tomarket anywhere from the end of 2020 to the middle of 2021. To date, just two coronavirus vaccine hasbeen approved. Sputnik V – formerly known as Gam-COVID-Vac and developed by the Gamaleya ResearchInstitute in Moscow – was approved by the Ministry of Health of the Russian Federation on 11 August.Experts have raised considerable concern about the vaccine’s safety and efficacy given it has not yetentered Phase 3 clinical trials. A second vaccine in Russia, EpiVacCorona, has also been granted regulatoryapproval, also without entering Phase 3 clinical trials. Operation Warp Speed (OWS) is a collaboration ofseveral US federal government departments including Health and Human Services and its subagencies,Agriculture, Energy and Veterans Affairs and the private sector. OWS has selected three vaccine candidatesto fund for Phase 3 trials: Moderna’s mRNA-1273, University of Oxford and AstraZeneca’s AZD1222, andPfizer and BioNTech's BNT162.Within OWS, the US National Institutes of Health (NIH) has partnered with more than 18biopharmaceutical companies to accelerate development of drug and vaccine candidates for COVID-19(ACTIV). The COVID-19 Prevention Trials Network (COVPN) has also been established, which combinesclinical trial networks funded by the National Institute of Allergy and Infectious Diseases (NIAID): the HIVVaccine Trials Network (HVTN), HIV Prevention Trials Network (HPTN), Infectious Diseases Clinical ResearchConsortium (IDCRC), and the AIDS Clinical Trials Group.